SYM Financial Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

SYM Financial Corp’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$239K	Sell	4,235 -286	-6%	-$16.7K	0.02%	274
2025 Q4	$269K	Sell	4,521 -71	-2%	-$3.87K	0.03%	256
2025 Q3	$249K	Buy	+4,592	New	+$263K	0.03%	257
2025 Q2	–	Sell	-3,466	Closed	-$245K	–	423
2025 Q1	$245K	Buy	+3,466	New	+$233K	0.03%	212

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SYM Financial Corp's BMRN Position: Q1 2026 in Review

SYM Financial Corp reduced its BioMarin Pharmaceuticals (BMRN) stake by 6.3% in Q1 2026, selling an estimated $16.7K and leaving 4,235 shares worth $239K. The position accounts for 0.02% of the portfolio, ranked #274.

SYM Financial Corp first reported a position in BMRN in Q1 2025 and has held it in 4 quarters since. The position peaked at $269K in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

SYM Financial Corp held 4,235 shares of BioMarin Pharmaceuticals worth $239K as of Q1 2026.
SYM Financial Corp sold 286 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $16.7K.
BioMarin Pharmaceuticals made up 0.02% of SYM Financial Corp's portfolio in Q1 2026, its #274 holding.
SYM Financial Corp first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
SYM Financial Corp's BioMarin Pharmaceuticals position peaked at $269K in Q4 2025.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on SYM Financial Corp's 13F filing for Q1 2026, filed 8 May 2026.